Login to Your Account



Vaccines Firm Goes to Vivalis in All-Share Deal Worth $175M

By Nuala Moran
Staff Writer

Tuesday, December 18, 2012
LONDON – The French vaccines manufacturing technology company Vivalis SA is acquiring Austrian vaccines discoverer and developer Intercell AG, of Vienna, in an all-share deal valued at €133 million (US$175 million).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription